含Ⅲ型纖連蛋白域蛋白5(FNDC5)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法)
ELISA Kit for Fibronectin Type III Domain Containing Protein 5 (FNDC5)
FRCP2; Irisin; Fibronectin type III repeat-containing protein 2
- 編號(hào)SEN576Hu
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長(zhǎng)3h
- 檢測(cè)范圍15.6-1,000pg/mL
- 靈敏度最小可檢測(cè)劑量小于等于6.9pg/mL.
- 樣本類型serum, plasma, tissue homogenates and other biological fluids
- 下載 英文說明書 中文說明書
- 規(guī)格 48T96T 96T*5 96T*10 96T*100
- 價(jià)格 ¥ 3234 ¥ 4620 ¥ 20790 ¥ 39270 ¥ 323400
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
實(shí)驗(yàn)結(jié)果圖
-
標(biāo)準(zhǔn)曲線圖
-
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測(cè)含Ⅲ型纖連蛋白域蛋白5(FNDC5)，經(jīng)檢測(cè)與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè)，因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的含Ⅲ型纖連蛋白域蛋白5(FNDC5)（加標(biāo)樣品），重復(fù)測(cè)定并計(jì)算其均值，回收率為測(cè)定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 98-105 | 101 |
| EDTA plasma(n=5) | 81-94 | 84 |
| heparin plasma(n=5) | 87-96 | 91 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定，每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的含Ⅲ型纖連蛋白域蛋白5(FNDC5)，并倍比稀釋成1:2，1:4，1:8，1:16的待測(cè)樣本，線性范圍即為稀釋后樣本中含Ⅲ型纖連蛋白域蛋白5(FNDC5)含量的測(cè)定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 85-104% | 79-99% | 84-99% | 83-97% |
| EDTA plasma(n=5) | 89-98% | 80-94% | 92-99% | 86-101% |
| heparin plasma(n=5) | 78-94% | 80-90% | 85-93% | 98-105% |
穩(wěn)定性
經(jīng)測(cè)定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品及樣本）100µL，37°C孵育1小時(shí)；
3. 吸棄，加檢測(cè)溶液A100µL，37°C孵育1小時(shí)；
4. 洗板3次；
5. 加檢測(cè)溶液B100µL，37°C孵育30分鐘；
6. 洗板5次；
7. 加TMB底物90µL，37°C孵育10-20分鐘；
8. 加終止液50µL，立即450nm讀數(shù)。
實(shí)驗(yàn)原理
將含Ⅲ型纖連蛋白域蛋白5(FNDC5)抗體包被于96孔微孔板中，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本，其中的含Ⅲ型纖連蛋白域蛋白5(FNDC5)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的含Ⅲ型纖連蛋白域蛋白5(FNDC5)抗體，將未結(jié)合的生物素化抗體洗凈后，加入HRP標(biāo)記的親和素，再次徹底洗滌后加入TMB底物顯色。TMB在過氧化物酶的催化下轉(zhuǎn)化成藍(lán)色，并在酸的作用下轉(zhuǎn)化成最終的黃色。顏色的深淺和樣品中的含Ⅲ型纖連蛋白域蛋白5(FNDC5)呈正相關(guān)。用酶標(biāo)儀在450nm波長(zhǎng)下測(cè)定吸光度(O.D.值)，計(jì)算樣品濃度。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPN576Hu05 | 含Ⅲ型纖連蛋白域蛋白5(FNDC5)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPN576Hu06 | 含Ⅲ型纖連蛋白域蛋白5(FNDC5)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPN576Hu07 | 含Ⅲ型纖連蛋白域蛋白5(FNDC5)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPN576Hu02 | 含Ⅲ型纖連蛋白域蛋白5(FNDC5)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| EPN576Hu61 | 含Ⅲ型纖連蛋白域蛋白5(FNDC5)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPN576Hu03 | 含Ⅲ型纖連蛋白域蛋白5(FNDC5)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPN576Hu01 | 含Ⅲ型纖連蛋白域蛋白5(FNDC5)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| APN576Hu01 | 含Ⅲ型纖連蛋白域蛋白5(FNDC5)活性蛋白 | Cell?culture;?Activity?Assays. |
| APN576Hu61 | 含Ⅲ型纖連蛋白域蛋白5(FNDC5)活性蛋白 | Cell?culture;?Activity?Assays. |
| RPN576Hu04 | 含Ⅲ型纖連蛋白域蛋白5(FNDC5)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAN576Hu02 | 含Ⅲ型纖連蛋白域蛋白5(FNDC5)多克隆抗體 | WB; IHC; ICC; IP. |
| PAN576Hu04 | 含Ⅲ型纖連蛋白域蛋白5(FNDC5)多克隆抗體 | WB; IHC; ICC; IP. |
| PAN576Hu01 | 含Ⅲ型纖連蛋白域蛋白5(FNDC5)多克隆抗體 | WB; IHC; ICC; IP. |
| LAN576Hu71 | 含Ⅲ型纖連蛋白域蛋白5(FNDC5)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| SEN576Hu | 含Ⅲ型纖連蛋白域蛋白5(FNDC5)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMN576Hu | 含Ⅲ型纖連蛋白域蛋白5(FNDC5)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Diabetes Research and Clinical Practice | Serum irisin levels in new-onset type 2 diabetes [PubMed: 23369227] |
| Journal of diabetes and its complications | Lower circulating irisin is associated with type 2 diabetes mellitus [Pubmed: 23619195] |
| Horm Metab Res. | Inconsistency in circulating irisin levels: what is really happening [Pubmed:24459033] |
| Int J Obes (Lond). | Leptin administration activates irisin-induced myogenesis via nitric oxide-dependent mechanisms, but reduces its effect on subcutaneous fat browning in mice [Pubmed:25199621] |
| Molecular and Cellular Endocrinology | Fenofibrate (PPARalpha agonist) induces beige cell formation in subcutaneous white adipose tissue from diet-induced male obese mice [Pubmed:25576856] |
| journal of diabetes | Lower irisin level in patients with type 2 diabetes mellitus: A case-control study and meta-analysis [PubMed: 25494632] |
| The Journal of Maternal-Fetal & Neonatal Medicine | Maternal circulating levels of irisin in intrahepatic cholestasis of pregnancy [PubMed: 26689349] |
| Hormone and Metabolic Research | Lower Circulating Irisin Level in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis [Pubmed:27300472] |
| Nature Reviews Endocrinology | Physiology and role of irisin in glucose homeostasis. [pubmed:28211512] |
| Journal of Molecular and Cellular Cardiology | Irisin improves perivascular adipose tissue dysfunction via regulation of the heme oxygenase-1/adiponectin axis in diet-induced obese mice [pubmed:27638193] |
| Biochemical and Biophysical Research Communications | Irisin stimulates cell proliferation and invasion by targeting the PI3K/AKT pathway in human hepatocellular carcinoma [pubmed:28867187] |
| PLoS One | Differential actions of PPAR-α and PPAR-β/δ on beige adipocyte formation: A study in the subcutaneous white adipose tissue of obese male mice [Pubmed:29351550] |
| International Brazilian Journal of?Urology | The Diagnostic Value of FNDC5/Irisin in Renal Cell Cancer. [Pubmed:29522296] |
| Redox Biology | Irisin alleviates liver ischemia-reperfusion injury by inhibiting excessive mitochondrial fission, promoting mitochondrial biogenesis and decreasing oxidative?… [Doi: 10.1016/j.redox.2018.10.019] |
| Antioxidants & redox signaling | Low serum irisin concentration is associated with poor outcomes in patients with acute pancreatitis and irisin administration protects against experimental acute?… [Pubmed: 31250660] |
| Journal of Maternal-Fetal & Neonatal Medicine | Maternal serum, placental, and umbilical venous blood irisin levels in intrahepatic cholestasis of pregnancy [Pubmed: 31590596] |
| Biomed Pharmacother | Identification of irisin as a therapeutic agent that inhibits oxidative stress and fibrosis in a murine model of chronic pancreatitis [Pubmed: 32199226] |
| Irisin Improves Autophagy of Aged Hepatocytes via Increasing Telomerase Activity in Liver Injury [Pubmed: 31976032] | |
| Serum Irisin Predicts Posthepatectomy Complications in Patients with Hepatocellular Carcinoma [Pubmed: 31976024] | |
| DOMESTIC ANIMAL ENDOCRINOLOGY | The myokine Irisin: localization and effects in swine late medium and large antral ovarian follicle [Pubmed: 33120167] |
| Journal of Biomaterials and Tissue Engineering | The Combination of Aerobic and Resistance Exercise Induces Weight Loss via the PGC-1α/Irisin/UCP-1 Pathway [] |
| Evaluation of a recombinant bacillus calmette-guérin vaccine expressing P39-L7/L12 of Brucella melitensis: An immunization strategy against brucellosis in BALB/c … [] | |
| Eur Rev Med Pharmacol Sci | Salivary Irisin: potential inflammatory biomarker in recurrent apthous stomatitis patients [33755963] |
| Metabolites | Pattern of Adiponectin, Osteocalcin, Irisin, FGF-21, and MCP-1 According to the Body Size Phenotype: Could They Be Markers of Metabolic Health in Mexican-Mestizo?… [34822430] |
| Eat Weight Disord | Time-restricted feeding prevents metabolic diseases through the regulation of galanin/GALR1 expression in the hypothalamus of mice [34370270] |
| Ir J Med Sci | Eight-week exercise program improved the quality of life of Alzheimer's patients through functional, cognitive, and biochemical parameters [Pubmed:35604540] |
| Biomed Pharmacother | Irisin attenuates sepsis-induced cardiac dysfunction by attenuating inflammation-induced pyroptosis through a mitochondrial ubiquitin ligase-dependent?… [Pubmed:35653888] |
| Journal of King Saud University - Science | Interaction of nitric oxide synthase and mitochondrial ATP-sensitive potassium channels in protective impacts of combination therapy with irisin?… [] |
